Study of Secutrelvir in Participants With COVID-19
Starting soon · Phase 3 · Has a placebo group
Conditions studied: COVID-19
In brief
The main purpose of this study is to compare secutrelvir to placebo with respect to resolution of clinical symptoms in nonhospitalized participants with Coronavirus Disease 2019 (COVID-19) starting intervention within 48 hours of COVID-19 symptom onset.
Key facts
- Study ID
- NCT07746544
- Run by
- Shionogi
- People needed
- 1200
- Starts
- 2026-07-20
- Expected to finish
- 2027-08-31
- Last updated by the study team
- 2026-08-05
Who can join
Age: 12 and older, up to 74. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Japanese Site 1 — Multiple Locations, Japan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.